๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Minimal residual disease in chronic myeloid leukaemia patients

โœ Scribed by Andreas Hochhaus

Book ID
119755038
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
258 KB
Volume
15
Category
Article
ISSN
1521-6926

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Achievement of complete molecular respon
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
โœ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Michelina Santopietro; Ros ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 109 KB

Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cas